ProPublica
ProPublica is an independent, nonprofit newsroom that produces investigative journalism with moral force. Learn more.
Army Says War Records Gap Is Real, Launches Recovery Effort
Army Secretary John McHugh confirms to members of Congress that commanders in Iraq and Afghanistan failed to keep required field records: “Steps are being taken to make sure this doesn’t happen again.”
A Prolonged Stay: The Reasons Behind the Slow Pace of Executions
Opponents of the death penalty have hit upon an effective tactic: Learn who is making the lethal drugs used in executions and publicly shame them. Now, death penalty states are fighting to make the names of the drugs a state secret.
Congressmen to Hagel: Where Are the Missing War Records?
Unsatisfied with answers so far, leaders of the House veterans’ panel ask defense Secretary Chuck Hagel to explain why Army units can’t find field records from Iraq and Afghanistan.
Your Hospital May Be Hazardous To Your Health
As part of our ongoing investigation into patient safety, ProPublica reporters Marshall Allen and Olga Pierce produced this interactive story in collaboration with PBS Frontline and Ocupop during a May 11-16 hackathon.
FAQ: What You Need to Know About Prescriber Checkup
Frequently asked questions about our Prescriber Checkup news application.
Tracking State Bills Takes a Village: The Legislature Tracker Gets Launched in N.Y.
The MinnPost's open source Legislature Project makes it easy for newsrooms and individuals to identify and keep track of bills. Welcome, New York edition.
Reversal of Fortune: A Prosecutor on Trial
In the world of abusive prosecutors – where evidence can be withheld or invented in the name of winning convictions and without fear of punishment – Ken Anderson stands out: Anderson, a Texas prosecutor who abused his authority to help send an innocent man to prison for decades, now faces 10 years behind bars for his misconduct.
FDA Approved New Drug Despite Ongoing Investigation of Lab Misconduct
We’ve reported that the FDA has allowed drugs to stay on the market despite the fact that the research underpinning their safety and efficacy was tainted by fraud. New information shows that even after the FDA had cited the lab for falsifying data, the agency issued at least one brand new approval to a drug tested there.